Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 22:3:758.
doi: 10.1186/2193-1801-3-758. eCollection 2014.

Real life experience on the effect of Belimumab in patients with active systemic lupus

Morton Scheinberg  1 , Ricardo Golmia  1
Affiliations

Real life experience on the effect of Belimumab in patients with active systemic lupus

Morton Scheinberg et al. Springerplus. .

Abstract

Introduction: To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus.

Case presentation: Twenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period. A fatigue score was also evaluated at the same time.

Discussion and evaluation: Marked reduction of disease activity and fatigue score were observed in the patient group.

Conclusions: Belimumab is a novel form of therapy in patients with active systemic lupus erythematosus to be added in the standard of care particularly in patients with skin and joint symptoms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Skin vasculitis before and after treatment.
Figure 2
Figure 2
Disease activity and fatigue scale before and after six months.
See this image and copyright information in PMC

References

    1. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936–939. doi: 10.1136/ard.2006.065763. - DOI - PMC - PubMed
    1. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group A phase III, randomized placebo-controlled study of belimumab, monoclonal antibody that inhibits Blymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi: 10.1002/art.30613. - DOI - PMC - PubMed
    1. Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, for the PEARL-SC Study A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2014;73(4):1136–1140. - PubMed
    1. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Rheumatol. 2014;41:300–309. - PubMed
    1. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lúpus erythematosus. J Rheumatol. 1993;20(4):657–660. - PubMed

LinkOut - more resources